Baxter has come to the rescue of Ipsen and its partner Inspiration Biopharmaceuticals, which filed for Chapter 11 bankruptcy protection in October 2012, by agreeing to acquire the companies’ lead haemophilia programme OBI-1, a recombinant porcine factor VIII (rpFVIII) in development for congenital haemophilia A with inhibitors and acquired haemophilia A. Ipsen and Inspiration partnered in January 2010 with the aim of creating a market-leading haemophilia franchise, but after investing many millions of dollars in drug development Ipsen is now looking to exit this disease area.